Abcam Limited a life science company that focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company is a subsidiary of Danaher Corporation.
Business Segments
The company operates through several key business segments, each contributing to the provision of essential services and products to life scientists. The primary segments include:
Research Use Proteomic Tools: This segment focuses on developing antibodies...
Abcam Limited a life science company that focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company is a subsidiary of Danaher Corporation.
Business Segments
The company operates through several key business segments, each contributing to the provision of essential services and products to life scientists. The primary segments include:
Research Use Proteomic Tools: This segment focuses on developing antibodies used in various proteomic applications. It includes primary antibodies, secondary antibodies, immunoassays, and reagents for binding proteins and related substances. Products and tools in this category serve both academic and biopharma research needs.
Antibody Development for Clinical Applications: This segment specializes in creating high-quality antibodies for clinical diagnostics and therapeutics, supporting disease research and treatment pathways. This segment emphasizes collaborations with biopharma entities to develop custom solutions tailored to specific applications.
Biochemicals and Related Reagents: Beyond antibodies, the company provides a range of biochemicals and reagents that are essential in various laboratory applications. This includes proteins, peptides, polysaccharides, and a comprehensive suite of reagents designed for use in biological assays.
Diagnostic Applications: The company is increasingly involved in the development of diagnostic products. This segment includes companion diagnostics (CDx), in-vitro diagnostics (IVD), and point-of-care tests (POC) that cater to the evolving landscape of disease detection.
Biotherapeutics: This segment represents the company's endeavors in therapeutic discovery, where the focus lies on developing biotherapeutics for clinical use, streamlining the transition from discovery to commercialization.
Business Strategy
The company's business strategy is centered on enhancing its innovation capabilities, expanding market reach, and improving customer experiences. It prioritizes becoming a leading digital entity, extending its partnerships with biopharma companies, and ensuring commercial viability through effective scalability measures.
The company is establishing new lines of business by integrating advanced technologies into its operations, enhancing its product offerings, and targeting long-term profitability. Through sustained investments in research and development, the company is committed to generating a strong pipeline of innovative products, thus fortifying its market position.
Products and Services
The company's diverse portfolio encompasses a range of products and services dedicated to the life sciences community. The company provides:
Catalog Offerings: Including essential life science tools, such as antibodies, proteins, and assays. Specific products include recombinant RabMAbs, custom biochemicals, and immunoassay kits.
Custom Solutions: Tailored services for clients in the biotechnology and pharmaceutical sectors, adapting to the unique requirements of various projects and applications.
Cell-based Assays: A comprehensive suite of assays designed to facilitate cellular activity and internal processes studies.
GMP Manufacturing: The company manufactures IVD grade RabMAbs, ensuring compliance with stringent quality standards mandated for clinical applications.
Educational Resources: The company invests in customer education through various training programs, workshops, and informative resources to enhance user knowledge and product efficacy.
The company is committed to providing outstanding product quality and services, underpinned by continuous customer service enhancements and by aligning with industry best practices.
Geographical Markets
The company serves a global market with a considerable footprint across regions, such as North America, Europe, and Asia. Notably, the company has expanded its operational presence in key markets, including Waltham, MA, Cambridge, UK, and various locations in China and Europe.
Recent Acquisitions
Recent strategic acquisitions, such as Expedeon, BrickBio, and BioVision, have been critical in enhancing the company's product offerings and operational capabilities.
Research and Development
Research and Development (R&D) is pivotal to the company’s growth strategy. The company invests substantially in R&D initiatives, focusing on innovation, new product development, and overall enhancement of existing products. In 2022, the company reported R&D expenditures amounting to £56.1 million, reflecting its commitment to underlying technology and product improvements. The company has achieved notable advancements, expanding its portfolio significantly with thousands of in-house developed products, including recombinant proteins and cell lines.
Customers
The company caters to a diverse customer base consisting of over 1,730 clients globally. The customer categories include academic institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and research organizations. The increased focus on enhancing customer experience and satisfaction has contributed to high retention rates and sustained commercial relationships.
Sales and Marketing
The company employs a multi-channel marketing strategy to reach its customers effectively. The sales approach combines direct engagement through a dedicated sales force and distribution partnerships with leading suppliers in life science products. Promotional activities include digital marketing campaigns, participation in scientific conferences, and providing resources to researchers, thus enhancing its visibility in the marketplace.
History
The company was founded in 1998. It was incorporated in 1998. The company was formerly known as Abcam plc and changed its name to Abcam Limited in December 2023.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
